The incidence of lung cancer continues to rise worldwide. In Europe, among the European Community countries, cancer of the lung remains the leading cancer site in men. Among woman the mortality from lung cancer recently exceeds that from breast carcinoma. Therefore, the near future of personalized medicine lies in the development of multifunctional nanoparticles that can not only deliver desired therapeutics to specific molecular targets in cancer, but also treat and allow real-time monitoring of treatment with relevant imagining modalities.
GEMNS project addresses very ambitious and responsible transnational research program, development and innovation in the field of nanotechnology and nanomedicine for early lung cancer diagnostics and targeted anticancer therapeutics involving molecular sensing to X-ray radiotherapy.